Latest edition: 29 September 2026
Latest edition: 29 September 2026
AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio.
Novo forges this deal as the company looks to extend the lead secured from its first-to-market advantage in the oral weight loss drug arena.
This bet comes amid the strong industry buzz around the approval of Revolution Medicines’ OS-doubling pancreatic cancer treatment, Rasonque.
The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan.
Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective mechanism.
Novo has meanwhile been busy bolstering its pipeline amid a target to launch more than five multi-blockbusters by 2030.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
